Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study, page-207

Your spot on with your suggestion that PAR should delay pursuing DMOAD if it means significant added costs or delays, especially if PAR does not secure a partner to help fund the trials. However, if PAR can add a couple of secondary endpoints to 003 then it makes sense to pursue it, but we'll find out later this year what is required when we hear back from the FDA.

PR really needs to prioritise signing partnerships and focus on generating revenue. It has now got to the point where no one takes PRs rhetoric seriously. Lets hope he secures a partnership deal for MPS as part of his USA tour, else the board should seriously consider finding a replacement in the same way that Marco was let go.